NATCAPSUQ

Natural Capsules Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLAB
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations169.2187.2190.7
Other Income0.71.73.7
Total Income169.9188.9194.4
Expenses
+ Cost of Materials Consumed86.9103.2108.6
+ Changes in Inventories-2.0-0.9-3.8
+ Employee Benefit Expense14.121.022.0
+ Finance Costs6.310.913.4
+ Depreciation & Amortisation9.117.117.3
+ Other Expenses52.765.464.8
Total Expenses167.1216.9222.1
EBITDA17.5-1.6-0.8
EBIT8.4-18.7-18.0
Profit
PBT before Exceptional Items2.8-27.9-27.7
Pretax Income2.8-27.9-27.7
+ Current Tax1.23.64.2
+ Deferred Tax0.9-6.9-7.1
Tax Expense2.2-3.3-2.9
Net Income0.6-24.7-24.8
+ Net Income — Continuing Ops0.6-24.7-24.8
+ Other Comprehensive Income-0.4-0.0-0.0
Total Comprehensive Income0.2-24.7-24.8
Net Income to Common-17.1
Minority Interest-7.6
Per Share
Basic EPS0.22-23.84-24.01
Diluted EPS0.22-23.78-23.95
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.4-0.0
+ Items NOT to be Reclassified to P&L-0.0
+ Tax on Items NOT to be Reclassified0.40.0
Comprehensive Income — Owners of Parent-17.1
Comprehensive Income — Non-controlling Interests-7.6
Per Share — as-filed variants
Basic EPS — Continuing Operations0.22-23.84-24.01
Diluted EPS — Continuing Operations0.22-23.78-23.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit84.384.986.0
Gross Margin %49.8245.3345.09
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2.8-27.9-27.7
Net Income Adj (tax-effected)0.6-24.7-24.8
EPS Adj0.22-23.84-24.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.00
Filed Debt Equity0.40
Paid Up Equity Capital10.310.410.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.